R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair

[1]  A. Giordano,et al.  Differential expression and cellular distribution of γ‐tubulin and βIII‐tubulin in medulloblastomas and human medulloblastoma cell lines , 2010, Journal of cellular physiology.

[2]  M. Barbacid,et al.  Overall Cdk activity modulates the DNA damage response in mammalian cells , 2009, The Journal of cell biology.

[3]  I. Aldoss,et al.  Seliciclib in malignancies , 2009, Expert opinion on investigational drugs.

[4]  E. Schuuring,et al.  Methylation Markers for CCNA1 and C13ORF18 Are Strongly Associated with High-Grade Cervical Intraepithelial Neoplasia and Cervical Cancer in Cervical Scrapings , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[5]  George Iliakis,et al.  Backup pathways of NHEJ in cells of higher eukaryotes: cell cycle dependence. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  J. Parvin,et al.  Cdk1 participates in BRCA1-dependent S phase checkpoint control in response to DNA damage. , 2009, Molecular cell.

[7]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[8]  A. Hui,et al.  Therapeutic Efficacy of Seliciclib in Combination with Ionizing Radiation for Human Nasopharyngeal Carcinoma , 2009, Clinical Cancer Research.

[9]  M. Salto‐Tellez,et al.  Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer , 2009, Clinical Cancer Research.

[10]  V. Jobanputra,et al.  Distinct properties of cyclin-dependent kinase complexes containing cyclin A1 and cyclin A2. , 2009, Biochemical and biophysical research communications.

[11]  L. Otterbein,et al.  Multiple Cellular Mechanisms Related to Cyclin A1 in Prostate Cancer Invasion and Metastasis , 2008, Journal of the National Cancer Institute.

[12]  Marco Foiani,et al.  Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.

[13]  G. Schwartz,et al.  The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. , 2008, Cancer research.

[14]  S. Fulda,et al.  DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cells , 2007, International journal of cancer.

[15]  Michael Kinter,et al.  Interaction of a Cyclin E Fragment with Ku70 Regulates Bax-Mediated Apoptosis , 2007, Molecular and Cellular Biology.

[16]  P. Workman,et al.  A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.

[17]  S. Cho,et al.  Induction of cell apoptosis in non‐small cell lung cancer cells by cyclin A1 small interfering RNA , 2006, Cancer science.

[18]  Kum Kum Khanna,et al.  Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. , 2006, Cancer research.

[19]  A. Rivera,et al.  Cyclin A1 is a p53-induced gene that mediates apoptosis, G2/ M arrest, and mitotic catastrophe in renal, ovarian, and lung carcinoma cells , 2006, Cellular and Molecular Life Sciences CMLS.

[20]  Juan Leal,et al.  Discovery and evaluation of dual CDK1 and CDK2 inhibitors. , 2006, Cancer research.

[21]  Gordon K. Smyth,et al.  affylmGUI: a graphical user interface for linear modeling of single channel microarray data , 2006, Bioinform..

[22]  A. Fischer,et al.  Cernunnos, a Novel Nonhomologous End-Joining Factor, Is Mutated in Human Immunodeficiency with Microcephaly , 2006, Cell.

[23]  D. Lane,et al.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. , 2005, Cancer research.

[24]  David P Lane,et al.  A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. , 2005, Blood.

[25]  J. Schellens,et al.  Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). , 2005 .

[26]  S. West,et al.  CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair , 2005, Nature.

[27]  G. Enders,et al.  Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. , 2005, Cancer research.

[28]  Mamoru Fukuda,et al.  Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. , 2005, Cancer research.

[29]  Conrad A. Nieduszynski,et al.  The Cyclin A1-CDK2 Complex Regulates DNA Double-Strand Break Repair , 2004, Molecular and Cellular Biology.

[30]  K. Helin,et al.  E2F target genes: unraveling the biology. , 2004, Trends in biochemical sciences.

[31]  Kevin Camphausen,et al.  Transcriptional signature of flavopiridol-induced tumor cell death. , 2004, Molecular cancer therapeutics.

[32]  K. Camphausen,et al.  Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. , 2004, Molecular cancer therapeutics.

[33]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[34]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[35]  J. Bourhis,et al.  Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. , 2003, Cancer research.

[36]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[37]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[38]  A. Almasan,et al.  Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells , 2000, Oncogene.

[39]  Heinz Ruffner,et al.  BRCA1 Is Phosphorylated at Serine 1497 In Vivo at a Cyclin-Dependent Kinase 2 Phosphorylation Site , 1999, Molecular and Cellular Biology.

[40]  H. Koeffler,et al.  Cloning of the cyclin A1 Genomic Structure and Characterization of the Promoter Region , 1999, The Journal of Biological Chemistry.

[41]  Jean Y. J. Wang.  Cellular responses to DNA damage. , 1998, Current opinion in cell biology.

[42]  A. Lewellyn,et al.  Ionizing radiation induces apoptosis and elevates cyclin A1-Cdk2 activity before but not after the midblastula transition in Xenopus. , 1997, Molecular biology of the cell.

[43]  H P Koeffler,et al.  Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. , 1997, Cancer research.

[44]  C. Prives,et al.  Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases , 1995, Nature.

[45]  M. Barbacid,et al.  Cdk2 suppresses cellular senescence induced by the c-myc oncogene , 2010, Nature Cell Biology.

[46]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[47]  Patients with advanced non-small cell lung cancer (NSCLC) require “extensive assistance” from family members, representing a considerable cost burden, , 2007 .

[48]  Jiri Bartek,et al.  ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks , 2006, Nature Cell Biology.

[49]  D. S. Henderson.  DNA repair protocols : mammalian systems , 2006 .

[50]  A. Collins.  The Comet Assay , 2002 .

[51]  P. Olive.  The Comet Assay , 2002 .

[52]  A. Collins,et al.  Detection of alkylation damage in human lymphocyte DNA with the comet assay. , 2001, Acta biochimica Polonica.